[Federal Register: June 22, 2005 (Volume 70, Number 119)]
[Notices]               
[Page 36128]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr22jn05-75]                         

-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army

 
Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Provisional Patent Application Concerning Development 
of a Biosensor for Anthrax Therapeutics and Diagnostics

AGENCY: Department of the Army, DoD.

ACTION: Notice

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is 
made of the availability for licensing of the invention set forth in 
U.S. Provisional Patent Application Serial No. 60/653,230 entitled 
``Development of a Biosensor for Anthrax Therapeutics and Diagnostics, 
filed February 14, 2005. The United States Government, as represented 
by the Secretary of the Army, has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-ZA-J, 504 Scott Street, Fort 
Detrick, Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research & Technology Assessment, (301) 619-6664, both 
at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: This biosensor can be used for several 
different purposes namely: (1) Study toxin protein-protein 
interactions; (2) Screen anthrax therapeutic molecules such as 
antibodies and small molecules; (3) As a diagnostic tool to detect 
anthrax toxins in blood or urine samples.

Brenda S. Bowen
Army Federal Register Liaison Officer.
[FR Doc. 05-12308 Filed 6-21-05; 8:45 am]

BILLING CODE 3710-08-M